← All trials
NCT06742996
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 28, 2025
- Primary completion
- Mar 31, 2029
- Completion date
- Oct 30, 2032
- First posted
- Dec 19, 2024
- Last posted
- Dec 19, 2024
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BeOne MedicinesLead sponsor
- BeOne MedicinesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.